TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

April 23, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

TGRX-326

Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

collaborator

Sun Yat-sen University

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY